SCHEMBL3763250

SCHEMBL3763250

CC(C)C(C(=O)N1CCN(CC(=O)N2CCN(C3CCC3)CC2)CC1)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
CHRM1 P11229 4/20 0.53
ALDH1A1 P00352 5/20 0.49
KDM4E B2RXH2 4/20 0.49
PARP1 P09874 1/20 0.46
NPSR1 Q6W5P4 2/20 0.45
PKM P14618 1/20 0.45
HTT P42858 1/20 0.45
GAA P10253 1/20 0.44
TSHR P16473 1/20 0.44
MAPT P10636 2/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
HRH3 Q9Y5N1 3/20 0.44
RGS12 O14924 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3774546 0.86 CHRM1 (0.54) MEN1KMT2ACHRM1ALDH1A1KDM4E
SCHEMBL3774785 0.86 ALDH1A1 (0.44) MEN1KMT2ACHRM1ALDH1A1KDM4E
SCHEMBL3770051 0.86 CHRM1 (0.56) CHRM1ALDH1A1KDM4EPARP1NPSR1
SCHEMBL3773262 0.83 CHRM3 (0.60) CHRM1ALDH1A1KDM4EPARP1NPSR1
SCHEMBL3765502 0.83 CHRM1 (0.48) MEN1KMT2ACHRM1ALDH1A1KDM4E
SCHEMBL13005947 0.83 CHRM3 (0.61) CHRM1ALDH1A1KDM4EPARP1NPSR1
SCHEMBL3767216 0.82 KDM4E (0.52) KMT2ACHRM1ALDH1A1KDM4EPARP1
SCHEMBL13004966 0.80 NPSR1 (0.67) MEN1KMT2AALDH1A1KDM4ENPSR1
SCHEMBL3767674 0.78 ALDH1A1 (0.74) MEN1KMT2AALDH1A1KDM4ENPSR1
SCHEMBL3770129 0.78 ALDH1A1 (0.80) MEN1KMT2AALDH1A1KDM4EPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 MEN1 3270/4885KMT2A 242/4885CHRM1 392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.